Rubicon Water Names Lukasz Hansdorfer as New CFO Following Andrew Bendall’s Retirement
NiveshIQ
NSE: RUBICON · Healthcare
Rubicon Research Ltd.
₹1,839.40▲ ₹49.40 (+2.76%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on RUBICON. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Rubicon Research Ltd.
Rubicon Research Limited is a specialty pharmaceutical company operating in India, the United States, and internationally, with a focus on developing products in areas such as analgesics, gastrointestinal, cardiovascular, and central nervous system, among others. The company's core business revolves around its proprietary technologies, including RubiSRL and RubiReten, which enable the formulation of sustained release liquids and gastro-retentive systems for drugs with poor solubility. Key revenue drivers for the company include its strategic acquisitions and robust product portfolio, which have contributed to a 52% revenue growth in Q1 FY27, reaching ₹1754 Cr in revenue and ₹247 Cr in net income. Recent developments, such as the company's strong Q1 FY27 performance, have led to an increase
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹854.00 Cr +116.80% | ₹1,284 Cr +50.40% | ₹1,754 Cr +36.60% |
| EBITDA Margin | 18.15% | 19.94% | 23.26% |
| Net Profit | ₹91.00 Cr | ₹134.00 Cr +47.30% | ₹246.73 Cr +84.10% |
| EPS | ₹5.98 | ₹8.72 | ₹15.52 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Rubicon Water Names New CFO as Company Continues Global Growth
Rubicon Water Appoints Lukasz Hansdorfer as CFO Following Andrew Bendall's Retirement
🔒
+ 3 more stories about Rubicon Research Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹534 Cr, PAT ₹85 Cr, EPS ₹5.13, EBITDA margin 25.2%. Growth context: revenue QoQ +4.0%, PAT QoQ +10.4%. Street verdict: strong beat, revenue surprise +4.2%, PAT surprise +16.7%.
Recent corporate activity underscores the importance of product launches, approvals, and therapy-mix improvement, as wel...
The company's FY26 performance was marked by revenue of ₹1, 754 Cr, PAT of ₹247 Cr, an EBITDA margin of 23.3%, and EPS o...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for RUBICON
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track RUBICON alongside your other holdings
Unlock full RUBICON research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Rubicon Research Ltd.?
NiveshIQ detects active intelligence signals for Rubicon Research Ltd. (RUBICON) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Rubicon Research Ltd.?
Rubicon Research Ltd. operates in the Healthcare sector with a market capitalisation of ₹3,036,704.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.